The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.

Chronic obstructive pulmonary disease (COPD) burden remains high in underdeveloped regions of China despite a decline in ...

Global medical companies are launching hundreds of state-of-the-art technologies in the medical product pavilion of the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...

Regeneron recently secured approval for Dupixent in treating Chronic Obstructive Pulmonary Disease (COPD) in the European Union, with a pending approval decision in the United States expected in the ...

Profits at China’s industrial firms in September declined at a faster pace than a month earlier, as deflationary pressures sap the strength of corporate finances. Last month’s industrial ...

Sept industrial profits -27.1% y/y vs -17.8% y/y in August Jan-Sept profits -3.5% y/y vs +0.5% y/y in Jan-August China ramps up policy stimulus to spur growth BEIJING, Oct 27 (Reuters ...

Dupixent is now approved for COPD in more than 30 countries, including the US and China, where COPD is a huge unmet medical ...

driven mainly by sales in Japan and China. Dupixent was approved for its sixth indication — chronic obstructive pulmonary disease (COPD) — in Europe in July and in the United States in September 2024, ...